Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Clade Therapeutics

Main focus: Novel stem cell-derived cellular therapies

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: Undisclosed

Funding stage: Private

Location: Cambridge, MA, USA


Clade Therapeutics is focused on the development of next-generation cellular therapies, applying its induced pluripotent stem cell (iPSC)-based platform. Using its technology, it is able to generate iPSC-derived adult T, natural killer (NK) and B cells. The company is co-founded by Chad Cowan, a CRISPR Therapeutics co-founder, however, exactly how gene editing is used in the cell therapies under development has not yet been undisclosed.


HashtagClade Therapeutics

Company: Clade Therapeutics
Search CRISPR Medicine